Water soluble medicament sustained-release tablets and preparation method thereof

Abstract

The invention discloses water soluble medicament sustained-release tablets, which comprise the following components in part by weight: water soluble medicament 1-30, octadecanol 5-70, Eudragite L 100-55 2-50, talcpowder 2-30 and lactose 2-30. The water soluble medicament may be galanthamine hydrobromide, captopril, metoprolol tartaric acid or pseudoephedrine hydrochloride. In the invention, the octadecanol serving as a hydrophobic auxiliary material and the Eudragite L 100-55 sreving as a water soluble polymer auxiliary are adopted, so the release speed of the medicament can be controlled properly. The Eudragite L 100-55 is insoluble in gastric juice, but dissolves in duodenal juice to make high-viscosity sticky liquid, and thus the release and diffusion speed of the medicament can be reduced. The talcpowder which is a hydrophilic matter insoluble in water plays a porogen role in the sustained-release tablets. In the invention, the release speed of the medicament is regulated by regulating the mixing ratio of the medicament to the auxiliary material. Thus, the release speed of an active medicament is controlled.

Description

technical field [0001] The invention relates to a water-soluble drug sustained-release tablet and a preparation method thereof. Background technique [0002] Alzheimer's disease, also known as Alzheimer's disease (AD), is a primary degenerative brain disease that occurs in old age and early old age, and refers to a persistent high-level neurological dysfunction, namely Impairments in memory, thinking, analysis and judgment, visuospatial recognition, emotion, etc., in the absence of disturbance of consciousness. The characteristic pathological changes are atrophy of the cerebral cortex, accompanied by β-amyloid deposition, neurofibrillary tangles, and a decrease in the number of large memory neurons. The course of the disease is long, about 3 to 20 years, and it is the "fourth killer" of the elderly's health after cardiovascular disease, cerebrovascular disease and cancer. In the United States, AD is the third most costly disease after heart disease and cancer. With the ac...

AI Technical Summary

Problems solved by technology

In 2001, the U.S. FDA officially approved the drug for the treatment of AD, and it is now on the market in 25 countries. There are already sustained-release tablets, sustained-release capsules and other dosage forms, but the dosage forms listed in my country are only tablets, capsules and injections. No sustained-release tablets, sustained-release capsules and other dosage forms

Cap sustained-release capsules are already on the market in foreign countries. Since the water-soluble drug itself dissolves quickly, its release is difficult to be blocked. There is no sustained-release variety of Cap on the market in China.

Images